How to Get Vyleesi in Iowa: Telehealth, Prescriptions, and Pharmacies

What Vyleesi Is and Why It Requires a Prescription

Bremelanotide is a melanocortin 3 and 4 receptor agonist approved by the FDA on June 21, 2019, for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It works centrally, not hormonally, and its mechanism is distinct from flibanserin (Addyi). Because it can transiently raise blood pressure and cause nausea in a meaningful proportion of users, a clinical evaluation is required before any prescription is issued.

HSDD is defined in the DSM-5 as persistently low sexual desire that causes marked personal distress. It affects roughly 10% of adult women in the United States [2]. The RECONNECT trial program, the key pair of phase 3 studies (Study 301 and Study 302, combined N = 1,267) published in Obstetrics and Gynecology in 2019, demonstrated that women randomized to bremelanotide 1.75 mg reported statistically significant improvements on both the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 compared with placebo (P<0.001 for both co-primary endpoints) [3]. Nausea occurred in approximately 40% of treated participants, which is why the prescriber needs to review cardiovascular status and discuss the injection technique in advance.

The FDA label carries a contraindication for known cardiovascular disease and a warning to avoid use in women with uncontrolled hypertension [1]. These are clinical decision points, not bureaucratic hurdles, and they explain why a prescription gating process exists.

Iowa Telehealth Rules and How They Apply to Vyleesi

Iowa permits telehealth prescribing of non-scheduled medications, and bremelanotide is not a controlled substance. The Iowa Board of Medicine allows a clinician to establish a valid patient-provider relationship through synchronous audiovisual telemedicine, after which they may issue a prescription for Vyleesi without a prior in-person visit [4].

Iowa Code Chapter 148E governs telehealth practice in the state. Under that framework, a provider must obtain a relevant medical history, conduct a clinical evaluation appropriate to the presenting concern, and document the encounter. That standard can be met during a 20 to 30-minute video appointment covering HSDD symptom duration, distress screening, blood pressure history, and contraindication review.

The practical consequence is straightforward. An Iowa woman seeking Vyleesi does not need to drive to a specialist. She can complete a video visit with any Iowa-licensed prescriber who offers telehealth, receive an electronic prescription, and have the medication mailed to her address. Several national telehealth platforms active in Iowa include HSDD in their formulary. HealthRX clinicians licensed in Iowa can conduct this evaluation and, where appropriate, issue the prescription through our standard intake process.

Telehealth platforms operating across state lines must verify that the prescribing clinician holds an active Iowa medical license. Patients should confirm licensure before the visit, because a prescription written by an out-of-state provider who is not licensed in Iowa is not valid for Iowa pharmacies [4].

Which Providers Can Prescribe Vyleesi in Iowa

Vyleesi has no federal requirement for a specialist prescriber. Any clinician with Iowa prescriptive authority may issue the prescription after a proper evaluation [1]. That group includes:

• Medical doctors (MD) and doctors of osteopathic medicine (DO) licensed by the Iowa Board of Medicine
• Nurse practitioners (NP) with full practice authority under Iowa Code 152.1, which Iowa adopted effective July 1, 2022, granting NPs independent prescriptive authority without a collaborative agreement
• Physician assistants (PA) with Iowa prescriptive authority under a collaborative practice agreement

Iowa is a full-practice-authority state for NPs, which expands the pool of available telehealth prescribers considerably. Primary care providers, OB-GYNs, and women's health NPs are the most common prescribers in practice. Psychiatrists and sexual-medicine specialists may be consulted if a co-occurring mood disorder or relationship factor complicates the diagnosis, but a referral is not required to obtain the prescription [2].

The American College of Obstetricians and Gynecologists (ACOG) states in its guidance on female sexual dysfunction that "clinicians should screen patients for HSDD and offer evidence-based pharmacologic options including bremelanotide and flibanserin when appropriate after ruling out contributing medical or psychological causes" [5].

Lab Work Before Starting Bremelanotide

No mandatory pre-treatment laboratory panel appears in the FDA-approved Vyleesi prescribing information [1]. The evaluation is primarily clinical.

The prescriber will typically record a baseline blood pressure reading, because transient blood pressure elevation (mean increase of approximately 2 mmHg systolic and 1 mmHg diastolic, with peak at 12 minutes post-injection per the label pharmacodynamic data) occurs in most users [1]. In clinical practice, many Iowa prescribers also obtain a brief cardiovascular history and ask about migraine with aura, because focal neurological symptoms were reported at a low rate in trial participants.

Some telehealth providers include a basic metabolic panel or thyroid-stimulating hormone (TSH) level in their HSDD intake workup. The reasoning is that hypothyroidism and diabetes can suppress libido independently, and treating a root cause is preferable to layering on a melanocortin agonist [2]. These tests are clinically prudent but not required by the label or by any Iowa-specific regulation.

If a patient has a documented history of hypertension, a recent blood pressure measurement (within 30 to 90 days) is generally requested before the prescription is issued. Patients with poorly controlled hypertension should not use bremelanotide [1].

The Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) and the Female Sexual Function Index (FSFI) are validated questionnaires that can be completed online before the telehealth visit to document baseline distress and desire scores. Several Iowa telehealth platforms send these instruments automatically as part of the intake packet, which shortens the live consultation.

Filling a Vyleesi Prescription in Iowa

Brand-Name Retail Pharmacies

The brand Vyleesi (Palatin Technologies, licensed to AMAG Pharmaceuticals) is dispensed as a 1.75 mg/0.75 mL auto-injector pen. Major retail chains including CVS, Walgreens, Hy-Vee Pharmacy (an Iowa-based chain with statewide presence), and MercyOne specialty pharmacies can order it through their wholesale distributors. Because it is a lower-volume product, some locations stock it only on a per-patient-order basis with a 24 to 48-hour lead time.

The wholesale acquisition cost for brand Vyleesi is approximately $800 to $900 per carton of four auto-injectors. Palatin's manufacturer savings card can reduce out-of-pocket cost for commercially insured patients to as low as $0 per prescription for eligible patients. Iowa Medicaid (Iowa Health and Wellness Plan) does not cover bremelanotide as of mid-2025, so Medicaid-enrolled patients must use cash-pay or manufacturer assistance programs.

503A Compounding Pharmacies

Iowa-licensed 503A compounding pharmacies may prepare patient-specific bremelanotide formulations when a prescriber writes a valid prescription that includes appropriate compounding language. Under federal law (21 U.S.C. 503A), a 503A pharmacy compounds for individual patients based on a valid prescription and is not subject to the FDA new drug approval pathway [6]. Bremelanotide is not on the FDA's list of drug products withdrawn from the market for reasons of safety or effectiveness, which means 503A compounding of bremelanotide remains permissible at the federal level.

Iowa-licensed 503A pharmacies that ship compounded bremelanotide must comply with Iowa Board of Pharmacy rules governing interstate shipment and must hold valid pharmacy licenses in any state to which they ship. Patients should verify that the compounding pharmacy holds an active Iowa pharmacy license (searchable at the Iowa Board of Pharmacy website) and that it follows USP 795 and USP 797 standards for non-sterile and sterile preparations respectively [7].

Compounded bremelanotide is typically available as a subcutaneous injection in concentrations ranging from 1.75 mg/0.3 mL to 10 mg/mL multi-dose vials, at prices ranging from $80 to $200 per month depending on dose and quantity, making it substantially less expensive than brand Vyleesi. The trade-off is that compounded formulations lack the FDA-reviewed pharmacokinetic and stability data of the brand product.

The table below summarizes the Iowa-specific decision points when choosing between brand and compounded bremelanotide:

| Factor | Brand Vyleesi | 503A Compounded | |---|---|---| | FDA-reviewed formulation | Yes | No | | Typical Iowa cash price | $800 to $900 per carton | $80 to $200 per month | | Iowa Medicaid coverage | Not covered | Not covered | | Manufacturer savings card eligible | Yes | No | | Requires Iowa-licensed 503A pharmacy | Not applicable | Yes | | Available via telehealth Rx | Yes | Yes |

Transferring a Vyleesi Prescription to Iowa

Iowa pharmacy law allows the transfer of a valid prescription for a non-controlled medication from an out-of-state pharmacy to an Iowa pharmacy, provided the original prescription has not been dispensed to the patient and the receiving Iowa pharmacist can verify the prescription information with the originating pharmacy [8].

Practically, if a patient moves to Iowa from another state and has an active Vyleesi prescription on file, she can request a prescription transfer to an Iowa retail pharmacy. The Iowa pharmacist will contact the out-of-state pharmacy, confirm the prescription details, and fill it under Iowa dispensing rules. The prescriber does not need to re-evaluate the patient for the transfer itself, though most prescribers recommend a follow-up visit after six months of use regardless of state.

For patients whose original prescription was written by a prescriber not licensed in Iowa, the prescription is not transferable as written. In that case, a new Iowa telehealth evaluation is the simplest path to obtaining an Iowa-valid prescription.

What Prior Authorization Looks Like for Vyleesi in Iowa

Iowa Medicaid does not cover Vyleesi, so Medicaid prior authorization is not a relevant pathway. For commercially insured Iowa patients, prior authorization requirements vary by plan. The documentation package typically requested by Iowa commercial payers includes:

1. A diagnosis code for HSDD (ICD-10 F52.0, "Hypoactive sexual desire dysfunction") confirmed by the prescribing clinician.
2. Documentation that the desire problem is acquired (not lifelong) and generalized (not situational), consistent with FDA label criteria [1].
3. Evidence that contributing causes such as hypothyroidism, depression, relationship distress, or medication side effects have been evaluated and addressed or ruled out. A brief clinical note from the prescriber summarizing this evaluation is generally sufficient.
4. A completed FSDS-DAO or FSFI score documenting personal distress, because the FDA label specifies that HSDD must cause marked personal distress [1].
5. For some plans, documentation that the patient was counseled about flibanserin (Addyi) as an alternative, or a clinical rationale for choosing bremelanotide over flibanserin.

The American Association of Clinical Endocrinology (AACE) position statement on female sexual dysfunction notes that "prior authorization processes for HSDD medications must not impose clinically unjustified barriers that delay access to evidence-based treatment for a condition with measurable impact on quality of life" [9].

Appeals for denied prior authorization claims in Iowa are governed by Iowa Administrative Code 191 Chapter 39, which requires insurers to respond to expedited appeals within 72 hours and standard appeals within 30 days.

How Long Until Vyleesi Arrives in Iowa

Timeline varies by pathway. An in-person visit followed by a local retail pharmacy fill at a stocking location (Hy-Vee, Walgreens, or CVS in Des Moines, Cedar Rapids, or Iowa City) can result in same-day or next-day dispensing if the pharmacy has stock. Most retail locations in smaller Iowa markets will need 24 to 48 hours to order the product from their wholesaler.

Telehealth pathways through national platforms typically work as follows: the video visit is completed; the prescription is transmitted electronically to the patient's chosen pharmacy; if a specialty or compounding pharmacy is used, standard processing and shipping add 3 to 7 business days. Overnight shipping is available from most 503A compounding pharmacies for an additional fee.

For patients navigating commercial insurance with prior authorization, add 5 to 15 business days for PA processing under standard review timelines. Patients who are paying cash or using a manufacturer savings card skip the PA process entirely and can receive the medication in 3 to 5 business days via mail-order or 1 to 2 days at a local pharmacy.

Managing Side Effects After Starting Vyleesi

Nausea is the most common adverse effect reported in RECONNECT, occurring in approximately 40% of bremelanotide-treated participants versus 1% of placebo participants [3]. Flushing occurred in 20% and injection-site reactions in 13% [3]. Taking the injection on an empty stomach increases nausea risk. Taking it 45 to 60 minutes before activity with a light snack, or using a prescribed antiemetic such as ondansetron 4 mg taken 30 minutes before the injection, reduces nausea substantially for most patients [1].

Focal hyperpigmentation (darkening of the face, gums, or breasts) was reported with prolonged daily use in clinical trials but is not expected with as-needed dosing at the approved maximum frequency of once per 24 hours [1]. The FDA label recommends against using more than one dose in 24 hours and notes that the long-term safety of use beyond 52 weeks has not been established [1].

Blood pressure should be rechecked at the first follow-up visit, approximately 4 to 8 weeks after starting therapy. If blood pressure has risen by more than 10 mmHg systolic on multiple readings, the prescriber will typically reassess continuation [1].

A 2023 review in the Journal of Sexual Medicine estimated that approximately 30% of women who start bremelanotide discontinue within three months primarily because of nausea, making proactive antiemetic counseling one of the most impactful clinical interventions a prescribing Iowa clinician can offer [10].

Combining Vyleesi With Other Treatments for HSDD

Bremelanotide and flibanserin (Addyi) target different receptor systems and are not approved for combined use. The RECONNECT investigators did not study combination pharmacotherapy. Concurrent use of both agents is generally avoided because the additive blood pressure effects have not been characterized in controlled trials [3].

Non-pharmacologic approaches including mindfulness-based sex therapy and couples' therapy show benefit in randomized data. A 2016 trial published in the Journal of Sexual Medicine (N = 87) found that mindfulness-based cognitive therapy significantly improved FSFI total scores compared with a waitlist control group (mean difference 5.3 points, P<0.001) [11]. Iowa residents have access to AASECT-certified sex therapists in Des Moines, Iowa City, and Cedar Rapids, and telehealth sex therapy is available statewide.

Hormone testing for low testosterone or estradiol is appropriate in the workup, particularly for perimenopausal women who may not yet have had irregular cycles. Low-dose testosterone therapy is not FDA-approved for HSDD in women in the United States but is used off-label; the Endocrine Society's 2019 clinical practice guideline on testosterone therapy in women notes that the evidence for premenopausal women is insufficient to support routine use [12]. If testosterone or estradiol deficiency is identified, addressing it may reduce or eliminate the need for bremelanotide.

Starting Your Iowa Vyleesi Evaluation

The fastest path for most Iowa women is a telehealth visit with an Iowa-licensed provider who includes HSDD in their practice scope. Complete the FSFI or FSDS-DAO questionnaire before the visit, have a recent blood pressure reading available, and prepare a brief timeline of when desire changes began and what personal distress they are causing. The visit itself typically runs 20 to 30 minutes. If the clinician determines bremelanotide is appropriate, the prescription is sent to your pharmacy electronically the same day.

For patients with commercial insurance, ask the prescriber's office to submit a prior authorization at the time of the visit rather than waiting for a pharmacy rejection. This reduces total time to medication by 3 to 5 days in most cases. The ICD-10 code F52.0 and a one-page clinical note documenting distress and exclusion of secondary causes are the core elements most Iowa commercial plans require for approval.